Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

Hi #MedTwitter! I’m Samer Salem, an #IMG from Lebanon researching Kidney Cancer at Brigham and Women's Hospital and applying for Internal Medicine residency. So excited to pursue my dream specialty! #Match2025 #InternalMedicine AAMC ID: 14538528

Hi #MedTwitter 👋 ! I’m Tamara Kadi, a US #IMG from American University of Beirut 🇱🇧 & a postdoc Pitt Division of GI, Hepatology & Nutrition. I’m excited to be applying for #InternalMedicine my dream specialty ⭐️ Passionate about health equity and tackling disparities in GI health. Let’s connect! ✨ #Match2025 Project IMG ™

It is difficult to break the bar reached wit CT+IO in adv NSCLC all PDL1 SKYSCRAPER adding antiTIGIT to CT+IO not ⬆️PFS/OS vs CT+IO, and more toxic. Even longer mOS with CT+IO alone New ⛔️ trial with anti-TIGIT Should we continue with anti-TIGIT in ling? Biomarkers? #ESMOImmuno24

Perfection 🇨🇦

⚠️Proud to finally have this in published format Dr. Rola Raafat Alameddine : Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study) mdpi.com/3144706 #mdpicurroncol

Thrilled to share this milestone with my incredible mentor, Normand Blais, MD . Here’s to making #LiquidBiopsy widely accessible in Quebec—empowering patients with cutting-edge tools to overcome cancer. #Oncology #CancerResearch mdpi.com/1718-7729/32/2…

Only Manchester United can make you feel like this

Non, M. Dubé, les médecins spécialistes ne quittent pas le travail à 16h le vendredi. Nous n'avons qu'un seul objectif: soigner nos patients, et ce, peu importe l'heure ou le jour de la semaine. Ce n'est pas d'un projet de loi que les patients ont besoin, mais d'un système bien

Un poste de fellow clinique est disponible pour le programme d’oncologie thoracique médicale du CHUM. Les applications sont ouvertes . Avis aux intéressés!

Keep up or get left behind #ASCO2025

It’s unfortunate how underutilized and understudied physical activity remains in cancer management. nejm.org/doi/full/10.10…

Proudly representing Canadian oncology at #ASCO25. The future looks bright!

Why is CM816 so important? After Patrick Forde beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…

It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25

Zongertinib (oral TKI) now U.S. FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter

La guerre de désinformation est lancée par le ministre de la santé. Toutes les fautes de gestion du système seront mises sur le dos des médecins. Fake news: le DSN a été mal planifié dès le départ. Le Dossier santé numérique a du plomb dans l’aile lapresse.ca/actualites/san…

🚨🔥OncoAlert Hot Off The Press. Just published JTO & JTO CRR, results of: ⭐️ #COCOON Trial 🔷The Very important #SupportiveCare randomized trial of: Enhanced Vs Standard #Prophylactic #Dermatologic Management during Tx with #Amivantamab/#Lazertinib in patients with #EGFR+

Changement d’approche pour les cancers gastriques opérables. À venir bientôt au 🇨🇦.